Dr. Daniel J. Canter, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 79
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: George Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
GA license 65462 · LA license 300441 · PA license MD432523
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northside Hospital Atlanta, GA
- Northside Hospital Forsyth Cumming, GA
- Northside Hospital Gwinnett Lawrenceville, GA
- Northside Hospital Cherokee Canton, GA
Medical groups
- Georgia Urology, PA (103 clinicians)
- Urological Professional Services, LLC (75 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 79
- Services billed
- 2,852
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 41 |
| Psa (prostate specific antigen) measurement, total | 50 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 20 |
| Established patient office or other outpatient visit, 40-54 minutes | 25 | 25 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Erleada (apalutamide) | 47 |
| Orgovyx (relugolix) | 20 |
| Tamsulosin Hcl Other prescribers in Decatur, GA | 19 |
| Cephalexin Other prescribers in Decatur, GA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 41 payments worth $5,962 in total to this clinician.
| Janssen Global Services, LLC | $3,510 |
|---|---|
| Janssen Biotech, Inc. | $1,012 |
| Accord Healthcare, Inc. | $532 |
| Tempus Ai, Inc | $175 |
| Ferring Pharmaceuticals Inc. | $153 |
| Merck Sharp & Dohme LLC | $96.12 |
| Sumitomo Pharma America, Inc. | $93.09 |
| Dendreon Pharmaceuticals LLC | $60.42 |
| Consulting Fee | $3,510 |
|---|---|
| Food and Beverage | $1,620 |
| Compensation for services other than consulting (speaking, faculty) | $833 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Global Services, LLC Nov 11, 2025 | Consulting Fee | $3,510 |
| Janssen Biotech, Inc. May 31, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $555 |
| Janssen Biotech, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $278 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $147,653 in research payments for these studies, mostly to the institutions running them.
- ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332 - A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants wit…
Janssen Research & Development, LLC - Study name not reported
Myriad Genetic Laboratories, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.